IN8bio's 'off-the-shelf' gamma delta T cells stave off relapse for high-risk leukemia patients in very early data cut
With eyes set on the future of cell therapy, researchers are looking to leverage a growing menagerie of immune cells to engineer a better generation of tumor fighters. One type showing early promise is gamma delta T cells, and now another biotech in that space is trotting out promising — if limited — results.
Three acute myeloid leukemia patients dosed with IN8bio’s off-the-shelf gamma delta T cells remained in remission after a stem cell transplant as long as 20 months after receiving their cells, offering an early vote of confidence for the small biotech’s approach, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
